trending Market Intelligence /marketintelligence/en/news-insights/trending/qtizrwca7nhpcgvjpyviog2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cellectar Biosciences prices $14.4M common stock, warrants offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cellectar Biosciences prices $14.4M common stock, warrants offering

Cellectar Biosciences Inc. priced its underwritten public offering of common shares and warrants to raise gross proceeds of $14.4 million.

The Madison, Wis.-based company is offering common shares at $4 apiece, accompanied by a five-year series E warrant to purchase 1 common share exercisable at $4 per share.

Cellectar is also offering buyers, who will own more than 4.99% of its outstanding shares, the option to purchase 1,114 series C convertible preferred shares at a public offering price of $10,000 per share and a series E warrant to purchase 2,500 common shares with an exercise price of $4 per share.

The series C preferred shares are convertible into 2,500 common shares at a conversion price of $4.00 per share.

The biopharmaceutical company has granted the underwriters an overallotment option to buy up to an additional 540,000 common shares and warrants to purchase up to 540,000 shares.

The offering is expected to close July 31, subject to customary closing conditions.

Ladenburg Thalmann & Co. Inc. is acting as the book-running manager, while CIM Securities LLC is serving as a co-manager for the offering.